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ABSTRACT
Progesterone receptor (PR) plays a critical role in
cell proliferation and differentiation, and its tran-
scriptional activity is known to be modulated by
cofactor proteins. In the present study, we demon-
strated that in the presence of progesterone, protein
inhibitor of activated STAT-3 (PIAS3) significantly
inhibited the PR transcriptional activity and
the expression of progesterone-responsive genes.
Reduction of endogenous PIAS3 by PIAS3 small-
interfering RNA enhanced PR transactivation in
a ligand-dependent manner. PIAS3 interacted with
PR both in vitro and in vivo and the interaction
was enhanced by progesterone. Furthermore, our
findings suggested that PIAS3 strongly induced
PRB sumoylation at three sites, Lys-7, Lys-388 and
Lys-531. In addition, novel roles in PRB nuclear
retention and transactivation were identified for
these sites. Our data also suggested that PIAS3
was recruited in a largely hormone-dependent
manner in response to a progesterone-responsive
promoter. Finally, we demonstrated that PIAS3
inhibited the DNA-binding activity of PR and influ-
enced its nuclear export as well as PR transactiva-
tion. Taken together, these data strongly suggested
that PIAS3 played an important physiological role in
PR function.
INTRODUCTION
Human progesterone receptor (PR) is a member of the nuclear
receptor superfamily of ligand-dependent transcription
factors and plays an important role in tissue development,
reproduction and homeostasis (1). Similar to other steroid
receptors, PR also contains a highly conserved DNA-binding
domain (DBD) located in the center and a C-terminal
hormone-binding domain (HBD). In addition, PR contains a
ligand-independent activation function (AF) domain, AF1,
located in the N-terminus upstream of the DBD and a
hormone-dependent domain, AF2, in the C-terminal HBD.
The inhibitory function (IF) domain is ﬂanked at AF1
N-terminus, which auto-inhibits the function of PR (2,3).
PRs are expressed in two isoforms, PRA and PRB. The two
isoforms of PR are identical in sequence except that PRA is
missing the far 164 residues N-terminal B-upstream segment
(BUS) region. This segment is the third AF domain, AF3,
which contributes to the different transcription activities
of PRA and PRB (4–7). Consequently, PRB is in general a
stronger transcription activator than PRA (8–12).
Similar to other steroid hormone receptors, PR is transcrip-
tionally inactive and remains sequestered in a complex
of heat-shock proteins in the absence of a ligand. Progestin
binding to PR causes a conformational change and dimer-
ization, resulting in the association of PR dimer with speciﬁc
co-activators and general transcription factors. Ligand recep-
tors then bind to DNA via speciﬁc progesterone response ele-
ments (PREs) located within the regulatory regions of target
genes (13–17).
Apart from speciﬁc ligand regulation, different types of
post-translational modiﬁcations, such as phosphorylation,
acetylation and ubiquitination, also regulate the steroid
hormone receptors transcriptional activation and/or stability
(18–23). Recently, a new covalent modiﬁcation of PR
has been described: SUMO (small ubiquitin-like modiﬁer)
modiﬁcation. SUMO modiﬁcation is accomplished by the
reversible attachment of SUMO family members to the
acceptor lysine residues located in the target proteins, similar
to ubiquitination, with the help of a set of enzymes. Even if
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doi:10.1093/nar/gkl691mechanistically similar to ubiquitination, the two processes
involve distinct enzymes and sumoylation does not promote
protein degradation. Sumoylation appears to regulate diverse
cellular processes, including speciﬁcation of the subcellular
localization of proteins, formation of subnuclear structures,
interactions between proteins, stability of proteins and
modulation of transcription factors (24–26).
Several studies have reported that SUMO-1 regulates the
hormone-induced transactivation of PR, since its overexpres-
sion promotes sumoylation of PRB at the site of Lys-388, and
very strongly enhances PR-mediated gene transcription.
However, the mutation of sumoylation site in the K388R
mutant also increased PR transactivation. Although it has
been speculated that the enhancement of PR transactivation
by SUMO-1 overexpression may be realized by the sumoyla-
tion of the coactivator SRC-1 (7,27), the molecular basis
by which SUMO-1 regulates PR transcriptional capacity
remains unknown and further studies are necessary to clarify
the process.
Recently, a family of PIAS proteins was described as
SUMO-E3 ligases for critical target proteins such as p53
(28,29), c-jun (29,30), LEF1 (31), androgen receptor
(32–34) and estrogen receptor (35). However, it remains to
be established whether PIAS3 was responsible for PR sumoy-
lation. In the present study, we showed for the ﬁrst time the
pattern of PRB sumoylation at three sites was strongly
induced by PIAS3. Overexpression of PIAS3 strongly inhib-
ited the progesterone-triggered transactivation of PRB with
different promoter or cells, and knockdown of endogenous
PIAS3 with small-interfering RNA (siRNA) increased the
PR transactivation. However, PIAS3 inhibited gene activation
by ligand-stimulated PRB in a manner that was independent
of PRB SUMO modiﬁcation. Our results indicated that
PIAS3 was recruited in a hormone-dependent manner to a
progesterone-responsive promoter. Finally, we demonstrated
that PIAS3 inhibited the DNA-binding activity of PR and
inﬂuenced its nuclear export, which mechanistically resulted
in PR transactivation.
MATERIALS AND METHODS
Plasmid constructions
PRA and PRB cDNA kindly provided by Professor O’Malley
(Baylor College of Medicine) were cloned into pXJ40-Myc
and pcDNA3.0-GAL4-DBD vectors. SUMO-1 and PIAS3
cDNA fragments generated by PCR were transferred into
pXJ40-HA and pcDNA3.0-Flag vectors. HA-tagged PIAS3
C334S mutant was generated by PCR-mediated site-directed
mutagenesis, where cysteine 334 was converted to serine.
Myc-tagged PRB mutants (K388R, K7/531R and K7/388/
531R) were generated by PCR-mediated site-directed muta-
genesis, in them lysine 7, 388 and 531 were converted to
arginine. For subcellular localization assays, the PIAS3
cDNAs were ampliﬁed and transferred into the pEGFP-N1
vector (Clontech Laboratories, Inc.). For Yeast two-hybrid
assay, PRB and its mutants D456–556 (DAF1), D556–642
(DDBD), D456–642 (DAF1-DBD), 456–642 (AF1-DBD)
were generated by PCR and cloned into pGADT7 vector,
and PIAS3 cDNA was inserted into pGBKT7 vector
(Clontech Laboratories, Inc.). To generatebacterial expression
vector for GST–PIAS3, the corresponding PIAS3 cDNA was
cloned in frame into pGEX-KG vector (Amersham
Pharmacia Biotech). The Renilla vector (pRL-TK) was pur-
chased from Promega and the luciferase reporter plasmid
pMMTV-Luc was kindly provided by Professor Palvimo
Jorma (University of Helsinki).
Immunofluorescence and fluorescence microscopy
For endogenous PIAS3 and PR location, T47D cells were
seeded in 60 mm plates on to glass coverslips and cultured
in medium containing phenol red-free DMEM (Hyclone) sup-
plemented with 5% charcoal dextran-treated fetal bovine
serum (BiochROM AG, Germany). The cells were treated,
or not, with progesterone (100 nM) (Sigma) for 2 h
before harvesting. Examining the effect of PIAS3 on PRB
location, HeLa cells were treated as described above. Twenty-
four hours after transfection using Lipofectamine 2000
(Invitrogen) with GFP–PIAS3 and Myc-PRB, the cells were
treated with progesterone (100 nM) for various time period.
For immunoﬂuorescence staining, the cells were ﬁxed
for 20 min at room temperature in 4% paraformaldehyde
in PBS, permeabilized in 0.1% Triton X-100 in PBS for
15 min and probed with primary and secondary antibodies.
Primary mouse monoclonal antibodies were used at the fol-
lowing concentrations: 1:100 anti-Myc antibody (Santa Cruz
Biotechnology), 1:100 anti-PR antibody (Cell Signaling).
Primary rabbit polyclonal antibodies were used at the follow-
ing concentrations: 1:100 anti-PIAS3 antibody (Santa Cruz
Biotechnology). Secondary antibodies were FITC-labeled
anti-mouse or anti-rabbit antibodies and TRITC-labeled anti-
mouse antibody (Santa Cruz Biotechnology) and were used at
the following concentrations: 1:100 secondary antibodies.
Confocal imaging was performed using a Bio-Rad
Radiance 2100TM confocal laser system connected to a
Nikon TE300 microscope. The green ﬂuorescence was excited
with an argon laser (488 nm excitation line with 515 nm long
pass barrier ﬁlter) and red ﬂuorescence was simultaneously
excited with an He–Ne laser (543 nm excitation line with
570 nm long pass barrier ﬁlter).
Transfection and luciferase assay
293T, COS7, T47D and HeLa cells were routinely cultured in
DMEM containing 10% newborn calf serum at 37 Ci na
humidiﬁed atmosphere of 5% CO2 in air. For transfection,
the cells were seeded in 12-well plates containing phenol
red-free DMEM supplemented with 5% charcoal dextran-
treated fetal bovine serum. The cells were transfected with
0.2 mg of pMMTV-Luc reporter or DBD-Luc reporter plas-
mids, 0.05 mg of pXJ40-Myc-PRB (wild-type or mutants)
or pXJ40-Myc-PRA or pcDNA3.0-GAL4-DBD-PRB expres-
sion vectors, 0.02 mgo fRenilla reporter pRL-TK (Promega),
and 0.05–1.0 mg of the pXJ40-HA-PIAS3 expression vectors
and the respective empty vector was used to adjust the total
amount of DNA. The transfected cells were harvested 24 h
after treatment with 10 nM progesterone, and Fireﬂy and
Renilla luciferase activities were determined using a Dual-
Luciferase Reporter Assay System (Promega) and a TD-20/
20 luminometer (Turner Designs). Renilla luciferase activity
was used as an internal control for transfection efﬁciency. All
experiments were repeated at least three times.
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To map the region of PRB interacting with PIAS3, the yeast
two-hybrid assay was performed with a full-length PRB and
its mutants DAF1, DDBD, DAF1-DBD, AF1-DBD as prey
and pGBKT7-PIAS3 as the bait according to the manu-
facturer’s instructions (Clontech Laboratories, Inc.). AH109
yeast strain was co-transformed with pGBKT7-PIAS3 as
the GAL4–DBD and PRB fused to the pGADT7 plasmid.
All the transformants were plated on selective medium lack-
ing tryptophan, leucine, histidine and adenine, followed by
b-galactosidase assays.
GST pull-down assays
GST and GST fusion proteins were expressed and puriﬁed
according to the manufacturer’s instructions (Pharmacia).
Myc-PRB protein, obtained from the whole cell lysis of
293T cells, which were transfected with pXJ40-Myc-PRB
plasmid, was mixed with GST and GST–PIAS3 fusion pro-
tein bound to Sepharose beads in 1 ml of binding buffer
(20 mM Tris–HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA,
10% glycerol and 0.1% NP-40). The binding reaction was
carried out for 4 h at 4 C. Beads were washed for three
times in 1 ml washing buffer (the same as the binding buffer),
eluted in 10 mlo f2 · SDS–PAGE sample buffer and detected
by immunoblotting.
Immunoprecipitation and immunoblotting
For immunoprecipitation experiments, 293T cells were trans-
fected with the indicated plasmids. At 24 h post-transfection,
cells were washed twice with phosphate-buffered saline
(PBS) and lysed in IP lysis buffer (20 mM Tris–HCl,
pH 8.0, 150 mM NaCl, 1 mM EDTA, 0.1% NP-40, 10% glyc-
erol, 1 mM DTT and 1· cocktail). After brief sonication, the
lysates were cleared by centrifugation at 4 C. Supernatants
were incubated with mouse monoclonal anti-HA or anti-
Myc antibody for 4 h at 4 C and protein A/G–Sepharose
beads for 2 h at 4 C. The immunocomplexes were washed
three times with the same IP lysis buffer. The immunopre-
cipitated proteins were removed from the protein A/G
beads by boiling for 10 min in SDS-sample buffer and
immunoblotted with a monoclonal anti-Myc antibody, anti-
HA antibody and anti-Flag antibody (Santa Cruz Biotechnol-
ogy). For sumoylation experiments, cells were lysed in 0.5 ml
of RIPA buffer [50 mM Tris–HCl (pH 8.0), 150 mM NaCl,
5 mM EDTA, 15 mM DTT, 20 mM NEM and 1· cocktail]
followed by immunoprecipitation and immunoblotting.
Chromatin immunoprecipitation analysis
ChIP analysis was carried out using the ChIP assay kit
from Upstate Biotechnologies with minor modiﬁcations
of the protocol. HEK-293 cells were transfected with
pMMTV-Luc vector using Lipofectamine 2000 according to
the manufacturer’s protocol. Transfected cells were selected
in 500 mg/ml G418 (Invitrogen) for 2–3 weeks. Pooled clones
were cultured and then used for ChIP analysis. HEK-293
cells (1 · 10
7) stably expressing the MMTV promoter
were plated onto 60 mm dishes and were transfected with
1.0 mg of pXJ40-Myc-PRB or together with 2.0 mgo f
pXJ40-HA-PIAS3. HEK-293 cells were treated for 1 h with
vehicle or 100 nM progesterone, cross-linked with 1%
formaldehyde, and lysed in buffer containing SDS. Lysates
were sonicated to shear chromatin and cleared by centrifuga-
tion. Clear lysates were incubated with a control unrelated
antibody (IgG) or antibodies to Myc or HA (Santa Cruz
Biotechnologies), with protein A–Sepharose as an adsorbent.
Resins were washed in multiple buffers containing various
salts and detergents, followed by elution, reversal of cross-
links and isolation of DNA fragments. Following puriﬁcation,
the DNA was subjected to PCR ampliﬁcation using primers
MMTV-187 50-TGGTTACAAACTGTTCTTAAAACGAG-
GATG-30 and MMTV + 15 0-GCAAGTTTACTCAAAAAA-
TCAGCACTCTTT-30 under the following conditions:
30 cycles, 55 C, 1.5 mM MgCl2, 0.2 mM dNTPs, 5 U Taq
polymerase and 25 pmol of each primer. Ampliﬁed products
were normalized to similarly ampliﬁed input DNA of the
corresponding treatment groups (vehicle or progesterone).
An aliquot of 10 ml of each reaction was analyzed on 1.5%
1· Tris–borate/EDTA–agarose gels.
Real-time RT–PCR analysis
T47D cells were seeded in six-well plates containing phenol
red-free DMEM supplemented with 5% charcoal dextran-
treated fetal bovine serum and transfected using Lipofec-
tamine 2000 with 3.0 mg of the pXJ40-HA-PIAS3 expression
vectors, and the respective empty vector was used to adjust
the total amount of DNA. Eighteen hours after transfec-
tion, the cells were treated with 10 nM progesterone for
another 6 h.
Cell pellets were collected and RNA was extracted using
Trizol reagent (Invitrogen). The diluted RNA (1:100 for
cyclin D1 and GAPDH) was analyzed using real-time PCR
(Bio-Rad iCycler iQ real-time PCR system) with SYBR
Green Jumpstart  Taq ReadyMix  (Sigma) and probe for
the cyclin D1 gene (Forward primer, 50-CCAGAGTGATC-
AAGTGTGAC-30; Reverse primer, 50-GATGTCCACGTCC-
CGCAC-30) or the GAPDH (glyceraldehyde-3-phosphate
dehydrogenase) gene (Forward primer, 50-GGCTGAGAAC-
GGGAAGCTTGTCTAT-30; Reverse primer, 50-CAGCCTT-
CTCCATGGTGGTGAAGA-30). The program used was
40 cycles at 95 C for 2 min, 94 C for 15 s, 58 C for 30 s
and 72 C for 30 s.
RNA interference
From siRNA to target human PIAS3 was chemosynthesis and
from the PIAS3 target sequence was 50-TTGGTCATC-
TGAGTTCGGA-30, the scrambled sequence was 50-GCTT-
GTCCCGACAGAGTAG-30. The siRNA was transfected
into 293T cells using Lipofectamine 2000 according to the
manufacturer’s protocol. After 48 h, the cells were trans-
fected with PRB (0.05 mg), PRB-luciferase reporter
(0.2 mg) and siRNA again. Treated with progesterone for
another 24 h, cells were lysed for PRB-luciferase reporter
assay. The non-speciﬁc RNA duplex was used in control
experiments. The relative expression of endogenous PIAS3
was monitored by Western blotting of cell extracts isolated
from control or siRNA-treated cells, using a polyclonal anti-
body against PIAS3.
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DNA-binding activity of PR was analyzed by electrophoresis
gel mobility shift assay. Brieﬂy, in vitro translated protein PR
or the same amount of unprogrammed lysate (Promega) was
combined with the
32P-labeled PRE (50-GTTACAAAC-
TGTTCT-30) double-stranded oligonucleotide in binding
buffer [10 mM Tris, pH 7.5, 50 mM NaCl, 1 mM MgCl2,
4% glycerol, 0.5 mM EDTA, 0.5 mM dithiothreitol and
Nucleic Acids Research, 2006, Vol. 34, No. 19 55550.1 mg/ml poly(dT–dC)] in the presence or absence of proges-
terone (10 nM). The binding reaction (20 ml total volume)
was incubated at room temperature for 20 min and increasing
amounts of in vitro puriﬁed GST–PIAS3 fusion protein or the
same amount of GST were added to the binding reaction.
Reactions in antibody supershift analyses were incubated
with 1 mg of anti-PIAS3 antibody for 15 min at 4 C. Protein–
DNA complexes were resolved on a 5% native polyacry-
lamide gel and visualized by autoradiography.
RESULTS
PIAS3 inhibited hormone-dependent PR-mediated gene
transactivation
Previous studies in our laboratory suggested that, in the
presence of progesterone, the localization of PRB was altered
by PIAS3. To further elucidate the inﬂuence of PIAS3 on
PR-mediated gene transactivation, PR-negative 293T cells
were transfected with PRB, a MMTV luciferase reporter
containing PRE in the promoter and PIAS3. As shown in
Figure 1A, PRB exhibited a 25-fold induction of reporter
gene activation in response to progesterone. In addition, the
ligand-dependent transactivation of PRB was strongly
repressed, in a dose-dependent manner, by PIAS3 expression.
The effects of PIAS3 on PRB transactivation were not
restricted to a single cell type, as similar results were noted
in COS7 cells (Figure 1B). No differences were observed in
PRB protein levels between 293T and COS7 cells containing
transiently expressed PIAS3 and non-transfected controls
(data not shown), suggesting that the inhibition of PRB trans-
activation by PIAS3 was not due to a modulation of PRB
protein levels. Further examination of the transactivation
of endogenous PR in PR-positive T47D breast cancer cells
demonstrated that PIAS3 repressed progesterone-triggered
reporter gene transcriptional activity by 90% (Figure 1C).
In order to elucidate whether PIAS3 inhibition of PR tran-
sactivation was dependent on ligand stimulation, 293T cells
were co-transfected with PRB, PIAS3 and MMTV-Luc
reporter then treated with antiprogestin, RU486 (Figure 1D).
The data suggested that, in the presence of progesterone,
RU486 completely blocked the effects of PIAS3 on PRB
transcriptional activity. The effect of PIAS3 on transactiva-
tion of PRA was also examined in HeLa cells, and PIAS3
had the similar inhibitory effect on PRA transactivation
(Figure 1E).
We further investigated whether the inﬂuence of PIAS3
on PR function was independent of the promoter construct,
utilizing a Gal4–PRB fusion protein and a reporter plasmid
containing a Gal4-driven promoter. Similar to the MMTV
promoter, PIAS3 repressed Gal4–PRB transcriptional activ-
ity, but not Gal4–DBD (Figure 1F). These results indicated
that PIAS3 strongly repressed PR-dependent transactivation,
regardless of the promoter or cell type.
In order to investigate the role of endogenous PIAS3 in
PR-mediated transcriptional activation, 293T cells were
transfected with siRNA directed against PIAS3, or a control
siRNA, then co-transfected, 48 h later, with a MMTV
luciferase reporter construct together with the PRB expres-
sion vector. Cells were then stimulated with progesterone
(24 h). The results demonstrated that there was an obvious
increase in ligand-mediated PRB activity in PIAS3 siRNA-
transfected cells, compared to control siRNA (Figure 1G),
suggesting that the reduction of PIAS3 leads to increased
ligand-mediated PRB activity. Western-blot analysis demon-
strated that PIAS3 siRNA, but not control, speciﬁcally
reduced the expression of endogenous PIAS3 (Figure 1G),
further suggesting that PIAS3 inhibited PR transcriptional
activity in the presence of progesterone.
Previous research has suggested that cyclin D1 played an
important role in normal mammary gland development
(36,37). Cell cycle analyses of biphasic cell growth patterns
indicated that, following a single dose of progesterone, cyclin
D1 and cyclin E levels increased initially, as cells entered
S-phase (38). In order to corroborate luciferase reporter
assay data, the effects of PIAS3 on the expression of
endogenous PR target genes were examined. T47D cells
were transfected with PIAS3 in the presence and absence of
progesterone (10 nM, 6 h) before harvesting; RNA was
extracted, transcription of cyclin D1 was measured by real-
time RT–PCR and expression was normalized to GAPDH.
Although cyclin D1 mRNA levels were upregulated in
response to progesterone, with no changes noted in the
absence of progesterone, PIAS3 overexpression reduced the
ligand-induced increase in cyclin D1 mRNA (Figure 1H).
These data demonstrated PIAS3 efﬁciently decreased the
expression of endogenous PR-responsive genes, suggesting
that PIAS3 functioned as an inhibitor of PR-mediated
transactivation.
PIAS3 physically interacted with PRB
To further investigate the mechanism by which PIAS3
inhibited PRB transactivation, we examined whether there
was physical association between PRB and PIAS3. Although
previous research suggested that steroid nuclear receptors
Figure 1. PIAS3 strongly inhibited the transactivation of PR. (A) Inhibition of PRB transcriptional activity by PIAS3 in 293T cells. All treatments were as
follows, except when noted: cells were transiently transfected with pMMTV luciferase reporter construct together with an empty expression vector, Myc-PRB, or
varying amounts of HA-PIAS3 vectors, alone or in combination, as indicated. After transfection, cultures were treated with progesterone (10 nM) for 24 h (P+)
or not treated (P ), and cell extracts were prepared and measured for luciferase activity. (B) Inhibition of PRB transcriptional activity by PIAS3 in COS7 cells.
(C) Inhibition of PR transcriptional activity by PIAS3 in T47D cells with endogenous PR expression, PR was replaced by endogenous expression. (D) 293T cells
were transiently transfected with Myc-PRB expression vector together with HA-PIAS3 expression construct; antiprogestin RU486 (100 nM) was added as
indicated. (E) Inhibition of PRA transcriptional activity by PIAS3 in HeLa cells. (F) 293T cells were co-transfected with Gal4DBD–PRB chimeric constructs,
together with the DBD-luc reporter, or varying amounts of HA-PIAS3 vectors. (G) PIAS3 RNAi increased ligand-induced PRB transactivation. 293T cells were
transfected with either siRNA control or siRNA directed against PIAS3 and were co-transfected, 48 h later, with pMMTV-luc reporter plasmid and PRB plasmid
were then treated with progesterone (10 nM) or ethanol for 24 h, and luciferase activity was determined and normalized for transfection efficiency. Western-blot
analysis using PIAS3 antibody was performed to determine PIAS3 protein levels following siRNA transfection. (H) PIAS3 decreased cyclin D1 mRNA levels in
the presence of progesterone. T47D cells were transfected with PIAS3 expression construct as indicated. The cells were treated with control (0.1% ethanol)
vehicle or progesterone (10 nM, 6 h) before harvest, and total RNA was extracted. A real-time RT–PCR was performed for the cyclin D1 gene and normalized to
total GAPDH RNA, as described in Materials and Methods. The value for vehicle-treated cells was set at 1 (column 1). Mean ± SD (n ¼ 3).
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data of PR interaction with PIAS3 was not presented. We
utilized a GST pull-down assay to further elucidate the
physical association between PRB and PIAS3 in vitro. Our
results demonstrated that the recombinant fusion protein glu-
tathione S-transferase with PIAS3 (GST–PIAS3), but not
GST alone, was able to bind to PRB (Figure 2A). In addition,
we further veriﬁed the interaction between PRB and PIAS3
in intact cells (Figure 2B). A Myc-tagged PRB (Myc-PRB)
was co-expressed with HA-tagged PIAS3 in 293T cells.
Antibodies against the HA epitope precipitated a complex
of PRB and PIAS3, suggesting that the two proteins
physically interacted in living cells. Progesterone treatment
signiﬁcantly enhanced the association between PRB and
PIAS3, as demonstrated by both GST pull-down and co-
immunoprecipitation assays, which was consistent with pre-
vious results that the inhibition of PRB transactivation by
PIAS3 was only observed in cells stimulated with ligands.
In order to further identify the region of the PRB protein
that binds to PIAS3, PRB and its deletions were cloned into
a pGADT7 fusion protein expression vector then transfor-
med into S.cerevisiae strain AH109, together with pGBKT7
plasmids encoding GAL4-BD fused to PIAS3. As shown
in Figure 2C and D, the physical association between PRB
and PIAS3 was observed in yeast two-hybrid assays, with
amino acids 556–642 determined to be essential for the asso-
ciation of PRB with PIAS3 in yeast (Figure 2C).
PIAS3-induced sumoylation of PRB in vivo
Recently, the PIAS protein family was described as
SUMO-E3 ligases for critical target proteins such as p53
(28,29), c-jun (29,30), LEF1 (31), as well as the androgen
(32–34) and estrogen receptors (35). Although PIAS proteins
were shown to act as regulators of PR (39), it has not been
reported whether PIAS family proteins mediate the sumoy-
lation of PR. In order to clarify whether the effects of
PIAS3 on PR transactivation were associated with the
SUMO modiﬁcation of PR, 293T cells were transfected
with a Myc-PRB expression vector in the absence or presence
of a vector encoding HA-tagged SUMO-1. Blotting with
an anti-Myc monoclonal antibody detected a single
protein band of  115 kDa in cells expressing only PRB
(Figure 3A). In contrast, in the presence of progesterone,
cells co-expressing both PRB and SUMO-1 displayed an
additional slower-migrating band representing the sumoy-
lated PRB (Figure 3A). An HA-SUMO-conjugated PRB
band (Figure 3A) was detected, with an anti-HA antibody,
at the same position on the gel (Figure 3A). These data
suggested that the band represented sumoylated PRB.
Figure 2. PIAS3 interacts with PRB in vitro and in vivo.( A) Interaction of PRB with PIAS3 in vitro. GST–PIAS3 fusion proteins, immobilized on beads, were
mixed with cell lysates with Myc-PRB expression in the absence or presence of progesterone (100 nM). Bound proteins were subjected to SDS–PAGE followed
by western-blot analysis. (B) Interaction of PRB with PIAS3 in vivo. 293T cells were co-transfected with expression vectors for the Myc-tagged PRB and
HA-tagged PIAS3 as indicated. Lysates from transfected cells were immunoprecipitated using an anti-HA antibody, and the immunoprecipitates were probed
with an anti-Myc antibody. (C) Confirmation of the interaction of PRB with PIAS3 in yeast. The AH109 strain was co-transformed with GAL4-DBD–PIAS3 plus
different GAL4AD–PRB constructs as indicated in the schematic diagram, then scored for b-galactosidase (b-gal) activity. (++, positive strongly interaction;
+, positive interaction; -, no interaction). (D) PRB specifically interacted with PIAS3 in yeast. The AH109 strain was co-transformed as (C), then co-
transformants were isolated on the SD medium deficient in leucine and tryptophan (SD/ leu/ trp, left plate) or on the same medium lacking histidine and
adenine (selective medium, right plate).
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wild-type control, the PRB K388R mutant was not sumoy-
lated (Figure 3B), which suggests that PRB underwent
sumoylation at Lys-388, located at its N-terminal domain.
To further investigate the role of PRB sumoylation, we
performed transient transfection assays in 293T cells and
found that SUMO-1 expression signiﬁcantly increased PRB
transactivation in the presence of progesterone (Supplemen-
tary Figure 1A). Furthermore, mutation of sumoylation
site in the K388R mutant also increased the transactivation
ability of PRB (Supplementary Figure 1B). The result that
the non-sumoylated mutant was more active than the wild-
type receptor was similar to that reported previously (7,27).
In addition, we investigated whether PIAS3 protein was
capable of enhancing SUMO-1 attachment to PRB in intact
cells by co-expressing Myc-PRB, HA-SUMO-1 and Flag-
PIAS3 proteins in 293T cells, in the absence or presence
of progesterone. As shown in Figure 3C, in cells without
co-expression of the PIAS3 protein, a single band represent-
ing SUMO-modiﬁed PRB was obviously enhanced by the
addition of progesterone (Figure 3C). However, three slower-
migrating bands, representing sumoylated PRB, appeared
with PIAS3 co-expression, and the band representing
sumoylation of PRB in Lys-388 site was strongly enhanced
with progesterone treatment (Figure 3C). Given that this
result was based on overexpression of PIAS3, we examined
whether endogenous PIAS3 was involved in the sumoylation
of PRB. Knockdown of PIAS3 by RNAi decreased the
level of PRB sumoylation in the presence of progesterone,
as shown in Figure 3D. PIASy, an alternative PIAS family
member protein, only marginally enhanced PRB sumoylation
in the presence of progesterone (Supplementary Figure 3),
suggesting that PIAS3-promoted PRB sumoylation was
speciﬁc.
This is, to our knowledge, the ﬁrst report that, in the
presence of progesterone, PIAS3 expression strongly induced
a pattern of PRB sumoylation at three sites, including
Lys-388 and two novel sites.
Determination of PIAS3-induced PRB sumoylation sites
Mutagenesis studies were undertaken to further investigate
the sumoylation sites of PRB mediated by PIAS3 in vivo.
Examination of the PRB sequence (www.abgent.com/doc/
sumoplot) showed the possible presence of three consensus
motifs for SUMO-1 conjugation (yKXE) (24), including
Lys-388, as well as Lys-7 and Lys-531, which partially ﬁt the
consensus sumoylation sites (Figure 4A). 293T cells were
co-transfected with expression vectors encoding various
mutants of Myc-PRB (K388R or K7/531R or K7/388/531R)
and HA-SUMO-1 with or without Flag-PIAS3 (Figure 4B
and C). As shown in Figure 4B, substitution on Lys-388,
including the K388R and K7/388/531/R mutants, abolished
the ability of SUMO-1 conjugated to PRB, even when treated
Figure 3. Sumoylation of PRB and effects of PIAS3 on PRB. (A and B) 293T cells were transfected with expression plasmids encoding HA-SUMO-1 and
Myc-PRB or Myc-PRBK388R, incubated with or without progesterone (100 nM, 2 h), then lysed with RIPA buffer and immunoprecipitated (IP) with anti-Myc
antibody. The immunoprecipitates were probed with anti-Myc and anti-HA antibody, respectively. (C) 293T cells were transiently transfected with Myc-PRB,
HA-SUMO-1 and Flag-PIAS3 alone or in combination as indicated. After 24 h, the cells were treated with or without progesterone (100 nM, 2 h), then lysed and
immunoblotted with anti-Myc antibody. (D) 293T cells were transfected with either siRNA control or siRNA directed against PIAS3 and were co-transfected,
48 h later, with Myc-PRB and HA-SUMO-1 plasmids. Before being harvested, cells were treated with progesterone (100 nM) or ethanol for 2 h, and then lysed.
Anti-Myc and PIAS3 antibodies were used in western-blot analysis of cell lysates.
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Lys-7 and Lys-531 (K7/531R) did not abolish sumoylation
at Lys-388, although it was slightly lessened, suggesting
that mutations of Lys-7 and Lys-531 inﬂuenced Lys-388
sumoylation.
Ectopical expression of PIAS3 resulted in the strong
enhancement of PRB sumoylation in the presence of pro-
gesterone (Figure 4C). However, the effects of PIAS3
on sumoylation were still abolished in the PRB K388R
mutant (Figure 4C). Interestingly, sumoylation levels in the
K7/531R mutant were strongly diminished compared to
wild-type PRB, with only one band noted indicating Lys-388
sumoylation. The single band in the K7/531R mutant was
similar to the band in the absence of PIAS3, which was
relatively weaker than that in wild-type PRB and which
was further abolished in the K7/388/531R. These results
indicated that Lys-7 and Lys-531 were also involved in the
PIAS3-mediated sumoylation of PRB. Notably, the ability
of PIAS3 to stimulate PRB sumoylation was dependent on
Lys-388 sumoylation.
PIAS3 inhibition of PRB transactivation was
independent of PRB sumoylation
In order to further examine the role of PIAS3-enhanced
sumoylation on PR transcription regulation, 293T cells
were transfected with the same amount of PRB or its mutants
(K388R or K7/531R or K7/388/531R) and treated, or
not, with progesterone (10 nM, 24 h). Similar to previous
results, mutation of the sumoylation site in the K388R
mutant increased the transactivation ability of PRB (7,27).
Intriguingly, with the double substitution on both Lys-7 and
Lys-531, the activation of the reporter gene mediated
by K7/531R mutant was signiﬁcantly downregulated
(Figure 5A). Moreover, the K7/388/531/R mutant almost
failed to be transcriptionally activated by progesterone
(Figure 5A) whereas the protein levels of PR and its mutants
in 293T cells were quite similar (data not shown). We then
examined the ability of PIAS3 to inhibit gene activation
mediated by mutants unable to be modiﬁed by SUMO-1.
To this end, 293T cells were co-transfected with PRB or
its mutants (K388R, K7/531R or K7/388/531R), the
pMMTV-Luc reporter construct, and equal amounts of
PIAS3 expression vector. Cell lysates were prepared for
luciferase assays 24 h after progesterone treatment. Surpris-
ingly, the assays revealed that the transactivation of these
mutants, without sumoylation, was still inhibited by PIAS3
(Figure 5B). Most signiﬁcantly, the inhibition levels were
comparable with those observed in the wild-type PRB. In
addition, all PRB mutants still interacted with PIAS3 in the
presence of progesterone (Supplementary Figure 4).
We further investigated whether the PIAS3 C334S mutant
lacking E3 ligase activity (28,40) was able to inhibit PRB
transactivation as well as the wild-type. Similar to previous
assays, 293T cells were co-transfected with PRB, SUMO-1,
PIAS3 or PIAS3 C334S mutant then treated with or without
progesterone. As shown in Figure 5C, the PIAS3 C334S
mutant lost the ability to enhance PRB sumoylation in the
presence of progesterone, whereas PIAS3 inhibited the
transcriptional activity of PRB in a dose-dependent manner
(Figure 5D), with comparable capacity displayed by the
C334S mutant. These results indicated that the PIAS3 protein
was able to inhibit ligand-induced gene activation by PRB in
a manner that was independent of PRB SUMO modiﬁcations.
The nuclear localization of the transcription factor PR is
important for its activity (41–43); consequently, we further
investigated the intracellular localization of PRB and its
mutants. Confocal microscopy data indicated that both
wild-type PRB and its mutants predominantly resided in the
nucleus, with some cytoplasmic staining noted in the absence
of progesterone (Figure 5E, a–d). However, 2 h after pro-
gesterone treatment, the wild-type PRB was completely
translocated into the nucleus, but excluded from nucleoli
(Figure 5E, a and F). Although a similar distribution pattern
Figure 4. Determination of PIAS3-induced sumoylation sites in PRB. (A)A
schematic representation of PRB shows the sites corresponding to consensus
sequences for SUMO-1 conjugation. (B and C) 293T cells were transfected
with HA-SUMO-1 and Myc-PRB, Myc-PRB K388R, Myc-PRB K7/531R, or
Myc-PRB K7/388/531R in the presence or absence of PIAS3. Cells were
treated, or not, with progesterone (100 nM, 2 h) before harvesting. Cell
extracts were lysed with RIPA buffer and immunoprecipitated with anti-Myc
antibody. The immunoprecipitates were probed with anti-Myc and anti-HA
antibody, respectively.
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with progesterone (Figure 5E, b and F), >60% of the PRB
K7/388/531R mutant was still localized to the cytoplasm
in the ligand-treated HeLa cells (Figure 5E, d and F),
and  40% of the PRB K7/531R mutant staining was also
cytoplasmic, in the presence of progesterone (Figure 5E, c
and F). These results suggested that the localization of PRB
K7/531R and K7/388/531R differed from that of wild-type
PRB, and were consistent with the ligand-stimulated transac-
tivation of PRB and its mutants (Figure 5A). These data also
suggested that the three arginine substitutions on Lys-7,
Lys-388 and Lys-531 might have caused a conformational
change in PR, resulting in the inability of the mutant to
translocate to the nucleus in response to ligand stimulation.
PIAS3 destabilized PRB retention in the nucleus
Immunoﬂuorescence microscopy was used to visualize the
subcellular localization of endogenous PR and PIAS3 in
T47D cells treated, or not, with progesterone (2 h, 100 nM).
As shown in Figure 6A, endogenous PR was localized mainly
in the nucleus and cytosolic PR staining was visible in the
absence of progesterone. Progesterone treatment resulted in
the complete translocation of liganded-PRB from the cyto-
plasm to the nucleus. Detection of Myc-tagged PRB with
an anti-Myc antibody yielded the same localization as
endogenous PR (Figure 5E). PIAS3 resided mainly in the
nucleus, as dotted structures, with no changes induced by pro-
gesterone (Figure 6A). Overlay of PR and PIAS3 clearly
showed co-localization of both proteins as yellow-stained
areas (Figure 6A). These data indicated that the two endoge-
nous proteins co-localized in nuclear dot structures in T47D
cells, both in ligand-treated and in control untreated cells.
The effects of PIAS3 overexpression on PRB localization
at the subcellular level were then examined. HeLa cells
were co-transfected with GFP–PIAS3 and Myc-PRB, then
treated with progesterone (100 nM) and examined by
immunoﬂuorescence (Figure 6B). GFP-tagged PIAS3 expres-
sion was also observed as nuclear dots. Although Myc-PRB
mainly resided in the nucleus, some cytoplasmic staining
was noted, which did not change as a result of ectopical
expression of PIAS3 in the absence of progesterone
(Figure 6B, 0 h). After 30 min of progesterone treatment,
>85% of PRB (Figure 6C) translocated to the nucleus,
and co-localized with PIAS3 as nuclear dot structures
(Figure 6B). Interestingly, after 60 min of progesterone treat-
ment, some PRB staining was noted in the cytoplasm of cells
co-transfected with PIAS3, compared with cells, which only
expressed PRB (Figure 6B and C). Similar results were also
found in the PIAS3 C334S mutant, which lost the SUMO-E3-
ligase ability (Supplementary Figure 5). These data suggested
that, in the presence of progesterone, PIAS3 inﬂuenced
the localization of PRB and that one of the mechanisms by
which PIAS3 inhibited PR transcriptional activity was by
promoting the nuclear export of PR.
PIAS3 is recruited to endogenous PR-responsive
promoters
To further understand the mechanisms by which PIAS3 inhib-
ited PRB transactivation, chromatin immunoprecipitation
(ChIP) was used to determine whether PIAS3 and PRB
were recruited to promoters of progesterone-regulated genes
in vivo. HEK-293 cells, stably expressing the MMTV pro-
moter, were transfected with Myc-PRB or HA-PIAS3, then
treated, or not, with progesterone (100 nM, 2 h). Previous
research demonstrated that the MMTV promoter was highly
inducible by progesterone and contained multiple GRE/
PREs, located between 190 and 80 bp from the transcription
start site (44) (Figure 7A). Following formaldehyde cross-
linking and chromatin precipitation with anti-Myc and anti-
HA antibodies, the precipitated DNA was PCR ampliﬁed
with speciﬁc primers ﬂanking the PRE in the PR enhancer
region. In the absence of hormone, ChIP assay detected
minimal occupancy of the MMTV promoter by PRB, as
well as non-speciﬁc IgG background, whereas progesterone
treatment resulted in a substantial increase of PRB recruit-
ment by the MMTV promoter (Figure 7B). At the same
time, PIAS3 also associated with the MMTV promoter in
the presence of hormone (Figure 7B). Both PIAS3 and PRB
were speciﬁcally co-immunoprecipitated with HA- and Myc-
speciﬁc antibodies, respectively (Figure 7C). In addition,
HEK-293 cells stably expressing the MMTV promoter were
co-transfected with Myc-PRB and HA-PIAS3, then treated,
24 h after transfection, with progesterone for various times
points. As expected, PRB displayed a clear time-dependent
recruitment to the MMTV promoter. Importantly, PIAS3
also revealed a distinct time-dependent recruitment to the
MMTV promoter (Figure 7D). These results highlighted
the ﬁnding that PIAS3 and PRB were recruited in a largely
hormone-dependent manner to a progesterone-responsive
promoter in vivo.
To investigate whether PIAS3 inhibited the DNA-binding
activity of PRB, in vitro translated PRB and
32P-labeled
PRE were incubated with increasing amounts of in vitro puri-
ﬁed GST–PIAS3 fusion protein. As shown in Figure 7E,
PIAS3 inhibited PRB binding to the PRE sequence in a
dose-dependent manner. Antibody supershift experiments
showed that PIAS3 was present in the PR–PRE complexes
(Figure 7E). These data suggested that one possible mecha-
nism of PIAS3 action on PR transcription might be due to
the inhibition of PR binding to PRE.
DISCUSSION
The PR transcription factor plays an important role in tran-
scriptional regulation. In the current study, we have identiﬁed
PIAS3 as a novel PR-interacting partner utilizing a number
of in vitro and in vivo assays, including yeast two-hybrid,
in vitro GST pull-down and in vivo co-immunoprecipitation.
Overexpression of PIAS3 inhibited the transcriptional activ-
ity of PR and the expression of progesterone-responsive
genes. In sharp contrast, knockdown of endogenous PIAS3
increased PR transactivation, suggesting that PIAS3 played
an important role in PR signaling. Moreover, our results
showed that, in the presence of progesterone, PIAS3 expres-
sion strongly induced a pattern of PRB sumoylation at three
distinct sites. We further provided evidence that PIAS3
inhibited the DNA-binding activity of PRB and promoted
its nuclear export.
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sumoylation
There have been diverse reports on the inﬂuence of the PIAS
protein family on steroid receptor function. Kotaja et al. (39)
reported that while all PIAS proteins were able to co-activate
PR-dependent transcription, the degree of activation was
dependent on the receptor, the promoter and the cell type.
However, it was of note that with a more complex promoter
(the mouse mammary tumor virus promoter, pMMTV),
Tan et al. (45) found PIAS1 repressed PR-dependent transac-
tivation. Controversial results of the effects of PIAS family
proteins on steroid receptors might have resulted from the
fact that these studies used different promoter constructs
and cell types to measure transcriptional activity. Our ﬁnd-
ings, utilizing promoters of pMMTV-Luc and GAL4-Luc
reporters, consistently indicated that PIAS3 strongly inhibited
PR-mediated transactivation in 293T, HeLa, T47D and COS7
cells.
Sumoylation has emerged as an important mechanism of
gene expression control. Studies on a number of SUMO tar-
geted transcription factors revealed that steroid receptors
underwent sumoylation in response to ligand stimuli, which
involved the regulation of transcriptional activity (26,46),
including AR (32–34), ER (35) and PR (7,27). On the other
hand, PIAS family proteins were described as SUMO-E3 lig-
ases for critical target proteins, such as p53 (28,29), c-Jun
(29,30), LEF1 (31), androgen receptor (32–34) and estrogen
receptor (35). However, it remains to be established whether
PIAS3 was responsible for PR sumoylation while inhibiting
its transactivation. This is, to our knowledge, the ﬁrst demon-
stration that co-expression of PIAS3 strongly increased the
sumoylation of PRB in the presence of progesterone.
Interestingly, SUMO-1 modiﬁcation appears to have incon-
sistent effects on the transcriptional activity of PR (7,27).
Abdel-Haﬁz et al. (7) demonstrated that SUMO-1 modiﬁ-
cation repressed PR transcriptional activity, identifying the
consensus SUMO-1 binding motif as
387IKEE, within the
IF domain of PR. In contrast, SUMO-1 overexpression mark-
edly enhanced PR-mediated gene transcription. The contro-
versial results were partly due to the fact that SUMO-1 also
exerted effects on other proteins involved in PR transcription
regulation, such as SRC-1 (27). However, our ﬁndings clearly
indicated that PIAS3-induced SUMO modiﬁcation did not
involve in the repression of PR transcriptional activity
by PIAS3, as the PRB K388R and K7/388/531R mutants,
lacking sumoylation ability, were still repressed by PIAS3.
Moreover, the PIAS3 C334S mutant, lacking SUMO-E3-
ligase activity, still repressed PR transcriptional activity.
These ﬁndings clearly indicated that the PIAS3 protein
inhibited PR transactivation through a mechanism that was
independent of SUMO modiﬁcation of PR. Similar mecha-
nisms have also been reported with the regulation of other
transcription factors by PIAS proteins, including p53 (47),
STAT1 (48), ER (35), AR (32), LEF1 (31) and Elk-1 (49).
Whereas SUMO-E3-ligase activity of PIAS1 and PIASx-a
might be important for the regulation of androgen receptor
activity (33), but in the current study, PIAS3-induced
sumoylation had no effect on PR activity, suggesting that
PIAS proteins regulated the activity of transcription factors
through different mechanisms more than just SUMO-E3
ligases (50).
SUMO modification increased PRB stability
Although a relationship between SUMO modiﬁcation of PR
and PIAS3-mediated inhibition of its transcriptional activity
was not demonstrated, our ﬁndings established a pattern
of PRB sumoylation that was strongly induced by PIAS3,
and identiﬁed the positions of SUMO modiﬁcation at three
distinct sites. PRB sumoylation is known to occur on
Lys-388 (7,27). We found that PIAS3 also induced PRB
sumoylation at other two sites, Lys-7 and Lys-531, which
reside in a motif that partially ﬁts the YKXE consensus
sumoylation sites (24,26,46). Our data demonstrated that
the double mutant (K7/531R) had only one slower-migrating
band, corresponding to SUMO-modiﬁed PRB at Lys-388,
which was much weaker than that in wild-type PRB, whereas
the K7/388/531R completely eliminated PRB sumoylation in
the presence of PIAS3 in vivo. Intriguingly, in the presence
of PIAS3, the K388R mutant abrogated PRB sumoylation
at the two additional sites. These results indicated that PRB
sumoylation at these sites might occur in a sequential fashion
as mutation of Lys-388 blocked the sumoylation of Lys-7 and
Lys-531. Similar ﬁndings were reported with the NFAT1
protein (51).
Interestingly, our ﬁndings identiﬁed previously unexpected
roles for Lys-7 and Lys-531 in the transcriptional activity and
nuclear retention of PRB. Although the ligand-triggered
translocation of PRB into nucleus (43,52) was still observed
in the K388R mutant lacking sumoylation ability, the
K7/388/531R mutant failed to translocate in response to pro-
gesterone stimulation. Moreover, it ﬁtted well with the
impaired transactivation capacity and the K7/388/531R mut-
ant was no longer activated by ligand. Our results suggested
that mutants were still able to dimerize in the presence of
progesterone (Supplementary Figure 2), which contributed
to the nuclear localization of PR. This may have resulted
from the fact that the substitution of the three lysine sites
with arginine inﬂuenced PR dimensional conformation. The
results suggested that Lys-388, Lys-7 and Lys-531 were
important for the ligand-triggered transactivation of PRB.
Figure 5. PIAS3 inhibited PRB transactivation, independent of its sumoylation. (A) 293T cells were transiently transfected with pMMTV luciferase reporter
construct, Myc-PRB or various Myc-PRB mutant vectors. After transfection, cultures were untreated (P ) or treated with progesterone (10 nM, 24 h) (P+), and
cell extracts were prepared and measured for luciferase activity. Methods and treatment similar for all figure, except when noted. (B) Inhibition of PRB mutant
transactivation by PIAS3; HA-PIAS3 was co-transfected in 293T cells. (C) The RING finger domain of PIAS3 was required for increasing SUMO-1 modification
of PRB. 293T cells were transiently transfected with expression vectors containing Myc-PRB, HA-SUMO-1 and Flag-tagged wild-type or C334S mutant of
PIAS3, as indicated. Cell lysate was subjected to immunoblotting. (D) Inhibition of PRB transactivation by PIAS3 or its mutant; similar to Figure 1A, except
PIAS3 C334S mutant was added as indicated. (E and F) The subcellular localization of PRB and its mutants. Cultured HeLa cells were placed in a medium
containing charcoal-stripped serum then transiently transfected with Myc-PRB or its mutant expression vector. Cells were untreated (P ) or treated with
progesterone (100 nM, 2 h) (P+), 24 h after transfection, then subjected to immunofluorescence and confocal microscopy using a Myc-specific monoclonal
antibody. Scale bar: 20 mm. At least 300 transfected cells were scored for PRB and mutant subcellular distribution (E).
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on the role of SUMO modiﬁcation of PRB. Overexpres-
sion of either SUMO-1 or PIAS3 signiﬁcantly increased
the levels of PRB protein (Figure 4B and C), suggesting
that sumoylation increased the stability of PRB protein.
Moreover, PRB mutants, with no sumoylation ability, were
shown to be resistant to progesterone-induced degrada-
tion by ubiquitin-proteasome (data not shown), suggesting
that SUMO-1 and ubiquitin compete for conjugation to
the same lysines in PRB. Similar mechanisms have been
observed for Mdm2 (53), the E3 ubiquitin ligase for p53
and IkBa (54).
Figure 6. PIAS3 destabilized PRB retention in the nucleus. (A) The co-localization of wild-type PR and PIAS3 in T47D cells. T47D cells were cultured on
coverslips, placed in medium containing charcoal-stripped serum, and untreated (P ) or treated (P+) with progesterone (100 nM, 2 h) then subjected to
immunofluorescence using specific primary antibodies to PR and PIAS3. (B and C) PIAS3 destabilized PRB retention in the nucleus. HeLa cells were cultured in
medium containing charcoal-stripped serum, and co-transfected with Myc-PRB and GFP–PIAS3, treated with progesterone (100 nM) for 0, 0.5 or 2 h, then
subjected to immunofluorescence staining with Myc-specific monoclonal antibody. Scale bar: 20 mm. At least 300 transfected cells were scored for PRB
subcellular distribution (C).
Nucleic Acids Research, 2006, Vol. 34, No. 19 5563Figure 7. PIAS3 and PRB physically interacted and were recruited to a progesterone-inducible promoter in vivo.( A and B) ChIP was performed using HEK-293
cells stably expressing the MMTV promoter in the presence or absence of progesterone hormones. Primers specific for the MMTV promoter were used to amplify
the DNA associated with PR and PIAS3 in vivo.( C) Cleared ChIP lysis was first incubated with pre-immune serum, anti-Myc or anti-HA antibody as indicated,
then with protein A–Sepharose as an adsorbent. Resins were washed and bound proteins were detected by immunoblotting with antibodies to Myc or HA.
(D) Recruitment of PR and PIAS3 to progesterone-responsive promoters. HEK-293 cells stably expressing the MMTV promoter were cultured in the absence of
progesterone, and were then treated without (time 0) and with 100 nM progesterone for 30 and 60 min followed by ChIP analysis. (E) PIAS3 decreased protein–
DNA complex formation. Increasing amounts of in vitro purified GST–PIAS3 were mixed with in vitro translated PRB and
32P-labeled PRE in the presence of
progesterone (10 nM). Supershift experiments utilized anti-PIAS3 antibodies in the binding reactions, as indicated.
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The speciﬁc mechanism by which PIAS3 protein inhibited
PRB-activated transcription in vivo remains intriguing. Our
results showed that the interaction between PRB and PIAS3
protein destabilized PRB nuclear localization. It was noted
that PRB translocation to the nucleus seemed to be markedly
inhibitedbytheinteractionwithPIAS3afterprogesteronetreat-
ment (Figure 6B). However, evaluation of PRB and PIAS3
using confocal microscopy showed that within a short time
period (0.5 h) PRB completely entered the nucleus, while at a
later time point (2 h) PRB was partly cytosolic. Interestingly,
co-localization of PR and PIAS3 was observed predominantly
inthenucleus(Figure6A).Thesedatasuggesteditwasunlikely
that PIAS3 inhibited PRB translocation to the nucleus, but
rather destabilized PRB retention in the nucleus. The results
might explain, at least in part, the strong inhibition of PR tran-
scriptional activity by PIAS3 in the presence of progesterone.
The PIAS family is known to inhibit DNA-binding activity
(55). Consequently, it was important to determine whether
PIAS3 could form a complex with PRB on DNA, and
whether the presence of PIAS3 could, in part, affect PR
DNA-binding activity. Data from ChIP and gel shift assays
demonstrated that PIAS3 was recruited to endogenous
PR-responsive promoters and inhibited the DNA-binding
activity of PR (Figure 7). We then hypothesized that PIAS3
inhibited the interaction of PR with its target DNA by binding
to its DBD. It has been previously reported that the signal for
nuclear export of PR is contained within its DBD domain,
which functions as the export signal in multiple steroid
receptor family members (56,57). Our data showed PIAS3
which inﬂuenced the nuclear export of PRB (Figure 6). One
possible mechanism of action is that PIAS3 might contribute
to the DBD structure, which augments recognition of the
signal by the export machinery and by interacting with the
DBD domain of PR.
Alternatively, it is still possible that the observed inhibition
of PRB involved PIAS3-mediated SUMO modiﬁcation of
transcription regulators other than PRB, as PIAS3 over-
expression might enhance the SUMO modiﬁcation of many
proteins. Although the precise identity of these SUMO
conjugates is not known, they are likely to include numerous
transcriptional regulators known to undergo SUMO modiﬁ-
cation (24,26,27,46). It is conceivable that the enhanced
modiﬁcation of some of these factors can indirectly regulate
PRB activity. Consistent with this model, p53 (29) and LEF1
(31) are both inhibited by PIAS3 protein overexpression,
independent of their ability to be directly modiﬁed by SUMO.
In summary, our ﬁndings demonstrated that PIAS3 protein
signiﬁcantly inhibited PR-mediated transactivation, which
was accompanied by a strong induction of PR sumoylation
in a progesterone-dependent manner. The pattern of PIAS3-
triggered PRB SUMO modiﬁcation was identiﬁed at three
sites, Lys-7, Lys-388 and Lys-531. We further identiﬁed a
novel role for Lys-7 and Lys-531 in the nuclear retention of
PRB and the ligand-triggered transactivation of PRB. Our
data demonstrated that PIAS3 inhibited gene activation by
ligand-stimulated PRB in a manner that was independent of
PRB SUMO modiﬁcation. In addition, SUMO modiﬁcations
of PRB signiﬁcantly increased PRB stability, rendering it
resistant to progesterone-induced degradation. Finally, we
demonstrated that the mechanism by which PIAS3 protein
strongly inhibited PRB-activated transcription was mediated
by the interaction between PRB and PIAS3, which inhibited
the DNA-binding activity of PRB and inﬂuenced its nuclear
export.
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Supplemenatry data are available at NAR Online.
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